PET imaging in lymphoma

References

• Thompson CJ. Instrumentation. In: Principles and Practice of Positron Emission Tomography. Wahl RL (Ed.). Lippincott Williams & Wilkins, PA, USA 48–64 (2002).
   Google Scholar
• Finn RD, Schlyer DJ. Production of Radionuclides for PET. In: Principles and Practice of Positron Emission Tomography. Wahl RL (Ed). Lippincott Williams & Wilkins, PA, USA 1–15 (2002).
   Google Scholar
• Fowler JS, Ding Y. Chemistry. In: Principles and Practice of Positron Emission Tomography. Wahl RL (Eds). Lippincott Williams & Wilkins, PA, USA 16–47 (2002).
   Google Scholar
• Warburg O. Über den Stoffwechsel der Tumoren: arbeiten aus dem Kaiser Wilhelm-Institut für Biologie, Berlin-Dahlem. Springer, Berlin, Germany (1926).
   Google Scholar
• Yamamoto T, Seino Y, Fukumoto H et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem. Biophys. Res. Commun.170(1), 223–230 (1990).
   PubMed Web of Science ®Google Scholar
• Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer72(10), 2979–2985 (1993).
   PubMed Web of Science ®Google Scholar
• Au KK, Liong E, Li JY et al. Increases in mRNA levels of glucose transporters types 1 and 3 in Ehrlich ascites tumor cells during tumor development. J. Cell. Biochem.67(1), 131–135 (1997).
   PubMedGoogle Scholar
• Aloj L, Caraco C, Jagoda E, Eckelman WC, Neumann RD. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res.59(18), 4709–4714 (1999).
   PubMedGoogle Scholar
• Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J. Nucl. Med.34(3), 414–419 (1993).
   PubMed Web of Science ®Google Scholar
• Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. J. Nucl. Med.37(6), 1042–1047 (1996).
   PubMed Web of Science ®Google Scholar
• Wahl RL, Henry CA, Ethier SP. Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. Radiology183(3), 643–647 (1992).
   PubMedGoogle Scholar
• Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J. Nucl. Med.36(9), 1625–1632 (1995).
   PubMed Web of Science ®Google Scholar
• Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J. Nucl. Med.33(11), 1972–1980 (1992).
   PubMed Web of Science ®Google Scholar
• Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? J. Nucl. Med.36(10), 1854–1861 (1995).
   PubMedGoogle Scholar
• Higashi K, Clavo AC, Wahl RL. In vitro assessment of 2-fluoro-2-deoxy-D-glucose, l-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J. Nucl. Med.34(5), 773–779 (1993).
   PubMedGoogle Scholar
• Spaepen K, Stroobants S, Dupont P et al. [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur. J. Nucl. Med. Mol. Imaging30(5), 682–688 (2003).
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced hodgkin’s disease. international prognostic factors project on advanced hodgkin’s disease. N. Engl. J. Med.339(21), 1506–1514 (1998).
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P et al. Follicular lymphoma international prognostic index. Blood104(5), 1258–1265 (2004).
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N. Engl. J. Med.329(14), 987–994 (1993).
   PubMed Web of Science ®Google Scholar
• Bendini M, Zuiani C, Bazzocchi M, Dalpiaz G, Zaja F, Englaro E. Magnetic resonance imaging and 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: a prospective pilot study. MAGMA4(3–4), 213–224 (1996).
   PubMedGoogle Scholar
• Tomura N, Hirano H, Sashi R et al. Comparison of MR imaging and CT in discriminating tumor infiltration of bone and bone marrow in the skull base. Comput. Med. Imaging Graph.22(1), 41–51 (1998).
   PubMedGoogle Scholar
• Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J. Nucl. Med.28(3), 288–292 (1987).
   PubMed Web of Science ®Google Scholar
• Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer94(4), 879–888 (2002).
   PubMed Web of Science ®Google Scholar
• Wirth A, Seymour JF, Hicks RJ et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphoma. Am. J. Med.112(4), 262–268 (2002).
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Fischman A, Neuberg D et al. FDG–PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk. Lymphoma45(1), 85–92 (2004).
   PubMed Web of Science ®Google Scholar
• Yamamoto F, Tsukamoto E, Nakada K et al.18F-FDG PET is superior to 67Ga SPECT in the staging of non-Hodgkin’s lymphoma. Ann. Nucl. Med.18(6), 519–526 (2004).
   PubMedGoogle Scholar
• Moog F, Bangerter M, Diederichs CG et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology203(3), 795–800 (1997).
   PubMed Web of Science ®Google Scholar
• Bangerter M, Kotzerke J, Griesshammer M, Elsner K, Reske SN, Bergmann L. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol.38(6), 799–804 (1999).
   PubMed Web of Science ®Google Scholar
• Buchmann I, Reinhardt M, Elsner K et al. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer91(5), 889–899 (2001).
   PubMed Web of Science ®Google Scholar
• Schoder H, Meta J, Yap C et al. Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J. Nucl. Med.42(8), 1139–1143 (2001).
   PubMed Web of Science ®Google Scholar
• Sasaki M, Kuwabara Y, Koga H et al. Clinical impact of whole body FDG–PET on the staging and therapeutic decision making for malignant lymphoma. Ann. Nucl. Med.16(5), 337–345 (2002).
   PubMedGoogle Scholar
• Delbeke D, Martin WH, Morgan DS et al. 2-deoxy-2-[F-18]fluoro-D-glucose imaging with positron emission tomography for initial staging of Hodgkin’s disease and lymphoma. Mol. Imaging Biol.4(1), 105–114 (2002).
   PubMedGoogle Scholar
• Moog F, Bangerter M, Diederichs CG et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology206(2), 475–481 (1998).
   PubMed Web of Science ®Google Scholar
• Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur. J. Nucl. Med.25(7), 721–728 (1998).
   PubMedGoogle Scholar
• Hoh CK, Glaspy J, Rosen P et al. Whole-body FDG–PET imaging for staging of Hodgkin’s disease and lymphoma. J. Nucl. Med.38(3), 343–348 (1997).
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Warland V, Najjar F et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Nucl. Med. Commun.20(1), 13–20 (1999).
   PubMed Web of Science ®Google Scholar
• Shah N, Hoskin P, McMillan A, Gibson P, Lowe J, Wong WL. The impact of FDG positron emission tomography imaging on the management of lymphomas. Br. J. Radiol.73(869), 482–487 (2000).
   PubMed Web of Science ®Google Scholar
• Wiedmann E, Baican B, Hertel A et al. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin’s disease. Leuk. Lymphoma34(5–6), 545–551 (1999).
   PubMed Web of Science ®Google Scholar
• Partridge S, Timothy A, O’Doherty MJ, Hain SF, Rankin S, Mikhaeel G. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin’s disease: influence on patient management in a single institution. Ann. Oncol.11(10), 1273–1279 (2000).
   PubMed Web of Science ®Google Scholar
• Hueltenschmidt B, Sautter-Bihl ML, Lang O et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer91(2), 302–310 (2001).
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Beguin Y, Fassotte MF et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin’s disease. Haematologica86(3), 266–273 (2001).
   PubMed Web of Science ®Google Scholar
• Menzel C, Dobert N, Mitrou P et al. Positron emission tomography for the staging of Hodgkin’s lymphoma – increasing the body of evidence in favor of the method. Acta Oncol.41(5), 430–436 (2002).
   PubMed Web of Science ®Google Scholar
• Weihrauch MR, Re D, Bischoff S et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin’s disease. Ann. Hematol.81(1), 20–25 (2002).
   PubMed Web of Science ®Google Scholar
• Cohade C, Wahl RL. Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography – clinical use, interpretation methods, diagnostic improvements. Semin. Nucl. Med.33(3), 228–237 (2003).
   PubMedGoogle Scholar
• Naumann R, Beuthien-Baumann B, Reiss A et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin’s lymphoma. Br. J. Cancer90(3), 620–625 (2004).
   PubMed Web of Science ®Google Scholar
• Munker R, Glass J, Griffeth LK et al. Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin’s disease. Ann. Oncol.15(11), 1699–1704 (2004).
   PubMed Web of Science ®Google Scholar
• Hutchings M, Loft A, Hansen M et al. Position emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica91(4), 482–489 (2006).
   PubMed Web of Science ®Google Scholar
• Rigacci L, Vitolo U, Nassi L et al. Positron emission tomography in the staging of patients with Hodgkin’s lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. Ann. Hematol.86(12), 897–903 (2007).
   PubMed Web of Science ®Google Scholar
• Bangerter M, Moog F, Buchmann I et al. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG–PET) for accurate staging of Hodgkin’s disease. Ann. Oncol.9(10), 1117–1122 (1998).
   PubMed Web of Science ®Google Scholar
• Carr R, Barrington SF, Madan B et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood91(9), 3340–3346 (1998).
   PubMed Web of Science ®Google Scholar
• Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J. Nucl. Med.46(6), 958–963 (2005).
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Vogelsang H, Kletter K, Zettinig G, Chott A, Raderer M. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG–PET) for assessment of enteropathy-type T cell lymphoma. Gut52(3), 347–351 (2003).
   PubMed Web of Science ®Google Scholar
• Fuertes S, Setoain X, Lopez-Guillermo A et al. [The value of positron emission tomography/computed tomography (PET/CT) in the staging of diffuse large B-cell lymphoma]. Med. Clin. (Barc.)129(18), 688–693 (2007).
   PubMedGoogle Scholar
• Hoffmann M, Kletter K, Becherer A, Jager U, Chott A, Raderer M. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG–PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology64(4), 336–340 (2003).
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Chott A, Puspok A, Jager U, Kletter K, Raderer M. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG–PET) does not visualize follicular lymphoma of the duodenum. Ann. Hematol.83(5), 276–278 (2004).
   PubMed Web of Science ®Google Scholar
• Wohrer S, Jaeger U, Kletter K et al.18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG–PET) visualizes follicular lymphoma irrespective of grading. Ann. Oncol.17(5), 780–784 (2006).
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Beguin Y, Najjar F et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL). Ann. Oncol.12(6), 825–830 (2001).
   PubMed Web of Science ®Google Scholar
• Elstrom R, Guan L, Baker G et al. Utility of FDG–PET scanning in lymphoma by WHO classification. Blood101(10), 3875–3876 (2003).
   PubMed Web of Science ®Google Scholar
• Beal KP, Yeung HW, Yahalom J. FDG–PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. Ann. Oncol.16(3), 473–480 (2005).
   PubMed Web of Science ®Google Scholar
• Valencak J, Becherer A, Der-Petrossian M, Trautinger F, Raderer M, Hoffmann M. Positron emission tomography with [18F] 2-fluoro-d-2-deoxyglucose in primary cutaneous T-cell lymphomas. Haematologica89(1), 115–116 (2004).
   PubMed Web of Science ®Google Scholar
• Ambrosini V, Rubello D, Castellucci P et al. Diagnostic role of 18F-FDG pet in gastric MALT lymphoma. Nucl. Med. Rev. Cent. East Eur.9(1), 37–40 (2006).
   PubMedGoogle Scholar
• Najjar F, Hustinx R, Jerusalem G, Fillet G, Rigo P. Positron emission tomography (PET) for staging low-grade non-Hodgkin’s lymphomas (NHL). Cancer Biother. Radiopharm.16(4), 297–304 (2001).
   PubMed Web of Science ®Google Scholar
• Schoder H, Noy A, Gonen M et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J. Clin. Oncol.23(21), 4643–4651 (2005).
   PubMed Web of Science ®Google Scholar
• Radan L, Fischer D, Bar-Shalom R et al. FDG avidity and PET/CT patterns in primary gastric lymphoma. Eur. J. Nucl. Med. Mol. Imaging35(8), 1424–1430 (2008).
   PubMed Web of Science ®Google Scholar
• Kumar R, Xiu Y, Potenta S et al.18F-FDG–PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas. J. Nucl. Med.45(11), 1796–1803 (2004).
   PubMed Web of Science ®Google Scholar
• Roe RH, Finger PT, Kurli M, Tena LB, Iacob CE. Whole-body positron emission tomography/computed tomography imaging and staging of orbital lymphoma. Ophthalmology113(10), 1854–1858 (2006).
   PubMed Web of Science ®Google Scholar
• Basu S, Mahne A, Iruvuri S, Alavi A. Potential clinical role of fluorodeoxyglucose–positron emission tomography in assessing primary or secondary lymphomas of the parotid gland. Clin. Lymphoma Myeloma7(4), 309–314 (2007).
   PubMedGoogle Scholar
• Perry C, Herishanu Y, Metzer U et al. Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. Eur. J. Haematol.79(3), 205–209 (2007).
   PubMed Web of Science ®Google Scholar
• Suh C, Kang YK, Roh JL et al. Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck. J. Nucl. Med.49(11), 1783–1789 (2008).
   PubMed Web of Science ®Google Scholar
• Allen-Auerbach M, Quon A, Weber WA et al. Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol. Imaging Biol.6(6), 411–416 (2004).
   PubMed Web of Science ®Google Scholar
• Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J. Clin. Oncol.7(11), 1630–1636 (1989).
   PubMed Web of Science ®Google Scholar
• Rankin SC. Assessment of response to therapy using conventional imaging. Eur. J. Nucl. Med. Mol. Imaging30(Suppl. 1), S56–S64 (2003).
   Google Scholar
• Armitage JO, Weisenburger DD, Hutchins M et al. Chemotherapy for diffuse large-cell lymphoma – rapidly responding patients have more durable remissions. J. Clin. Oncol.4(2), 160–164 (1986).
   PubMed Web of Science ®Google Scholar
• Gupta RK, Gospodarowicz MK, Lister TA. Clinical Evaluation and Staging. In: Hodgkin’s Disease. Mauch P, Armitage JO, Diehl V, Hoppe R, Weiss LM (Eds). Lippincott Williams and Wilkins, PA, USA 223–240 (1999)
   Google Scholar
• Canellos GP. Residual mass in lymphoma may not be residual disease. J. Clin. Oncol.6(6), 931–933 (1988).
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Beguin Y, Fassotte MF et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin’s lymphoma. Haematologica85(6), 613–618 (2000).
   PubMed Web of Science ®Google Scholar
• Mikhaeel NG, Timothy AR, O’Doherty MJ, Hain S, Maisey MN. 18-FDG–PET as a prognostic indicator in the treatment of aggressive non-Hodgkin’s lymphoma-comparison with CT. Leuk. Lymphoma39(5–6), 543–553 (2000).
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann. Oncol.13(9), 1356–1363 (2002).
   PubMed Web of Science ®Google Scholar
• Hoekstra OS, Ossenkoppele GJ, Golding R et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J. Nucl. Med.34(10), 1706–1710 (1993).
   PubMed Web of Science ®Google Scholar
• Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J. Nucl. Med.43(8), 1018–1027 (2002).
   PubMed Web of Science ®Google Scholar
• Torizuka T, Nakamura F, Kanno T et al. Early therapy monitoring with FDG–PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma. Eur. J. Nucl. Med. Mol. Imaging31(1), 22–28 (2004).
   PubMed Web of Science ®Google Scholar
• Mikhaeel NG, Hutchings M, Fields PA, O’Doherty MJ, Timothy AR. FDG–PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann. Oncol.16(9), 1514–1523 (2005).
   PubMed Web of Science ®Google Scholar
• Haioun C, Itti E, Rahmouni A et al. [18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG–PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood106(4), 1376–1381 (2005).
   PubMed Web of Science ®Google Scholar
• Kostakoglu L, Goldsmith SJ, Leonard JP et al. FDG–PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer107(11), 2678–2687 (2006).
   PubMed Web of Science ®Google Scholar
• Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG–PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann. Oncol.16(7), 1160–1168 (2005).
   PubMed Web of Science ®Google Scholar
• Hutchings M, Loft A, Hansen M et al. FDG–PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood107(1), 52–59 (2006).
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Tani M, Fanti S et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin’s disease patients. Ann. Oncol.17(8), 1296–1300 (2006).
   PubMed Web of Science ®Google Scholar
• Gallamini A, Rigacci L, Merli F et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica91(4), 475–481 (2006).
   PubMed Web of Science ®Google Scholar
• Gallamini A, Hutchings M, Rigacci L et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian–Danish study. J. Clin. Oncol.25(24), 3746–3752 (2007).
   PubMed Web of Science ®Google Scholar
• Gallamini A, Viviani S, Bonfante V et al. Early interim FDG–PET during intensified BEACOPP therapy shows a lower predicitve value than during conventional ABVD chemotherapy. Haematologica92(Suppl. 5), 71 (2007).
   Web of Science ®Google Scholar
• Avigdor A, Bulvik S, Dann EJ et al. Combined ESCBEACOPP–ABVD therapy for advanced Hodgkin’s lymphoma patients with high IPS score: an effective regimen and low positive predictive value of early FDG–PET/CT. Haematologica92(Suppl. 5), 66 (2007).
   PubMed Web of Science ®Google Scholar
• Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J. Clin. Oncol.21(18), 3431–3439 (2003).
   PubMed Web of Science ®Google Scholar
• Oza AM, Ganesan TS, Leahy M et al. Patterns of survival in patients with Hodgkin’s disease: long follow up in a single centre. Ann. Oncol.4(5), 385–392 (1993).
   PubMed Web of Science ®Google Scholar
• Diehl V, Franklin J, Pfreundschuh M et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin‘s disease. N. Engl. J. Med.348(24), 2386–2395 (2003).
   PubMed Web of Science ®Google Scholar
• Bishu S, Quigley JM, Bishu SR et al. Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma. Leuk. Lymphoma48(8), 1548–1555 (2007).
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J. Clin. Oncol.17(4), 1244 (1999).
   PubMed Web of Science ®Google Scholar
• Juweid ME, Wiseman GA, Vose JM et al. Response assessment of aggressive non-Hodgkin’s lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J. Clin. Oncol.23(21), 4652–4661 (2005).
   PubMed Web of Science ®Google Scholar
• Becherer A, Jaeger U, Szabo M, Kletter K. Prognostic value of FDG–PET in malignant lymphoma. Q. J. Nucl. Med.47(1), 14–21 (2003).
   PubMedGoogle Scholar
• Brepoels L, Stroobants S, Verhoef G. PET and PET/CT for response evaluation in lymphoma: current practice and developments. Leuk. Lymphoma48(2), 270–282 (2007).
   PubMed Web of Science ®Google Scholar
• Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R, Buell U. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl. Med. Commun.19(11), 1055–1063 (1998).
   PubMed Web of Science ®Google Scholar
• de Wit M, Bumann D, Beyer W, Herbst K, Clausen M, Hossfeld DK. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann. Oncol.8(Suppl. 1), 57–60 (1997).
   PubMed Web of Science ®Google Scholar
• de Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld DK. 18FDG–PET following treatment as valid predictor for disease-free survival in Hodgkin’s lymphoma. Ann. Oncol.12(1), 29–37 (2001).
   PubMed Web of Science ®Google Scholar
• Freudenberg LS, Antoch G, Schutt P et al. FDG–PET/CT in re-staging of patients with lymphoma. Eur. J. Nucl. Med. Mol. Imaging31(3), 325–329 (2004).
   PubMed Web of Science ®Google Scholar
• Dittmann H, Sokler M, Kollmannsberger C et al. Comparison of 18FDG–PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin’s lymphoma. Oncol. Rep.8(6), 1393–1399 (2001).
   PubMed Web of Science ®Google Scholar
• Guay C, Lepine M, Verreault J, Benard F. Prognostic value of PET using 18F-FDG in Hodgkin’s disease for posttreatment evaluation. J. Nucl. Med.44(8), 1225–1231 (2003)..
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Beguin Y, Fassotte MF et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for post-treatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood94(2), 429–433 (1999).
   PubMed Web of Science ®Google Scholar
• Kazama T, Faria SC, Varavithya V, Phongkitkarun S, Ito H, Macapinlac HA. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. Radiographics25(1), 191–207 (2005).
   PubMed Web of Science ®Google Scholar
• Lang O, Bihl H, Hultenschmidt B, Sautter-Bihl ML. Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin‘s disease. Strahlenther. Onkol.177(3), 138–144 (2001).
   PubMed Web of Science ®Google Scholar
• Maisey NR, Hill ME, Webb A et al. Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? Eur. J. Cancer36(2), 200–206 (2000).
   PubMedGoogle Scholar
• Lavely WC, Delbeke D, Greer JP et al. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int. J. Radiat. Oncol. Biol. Phys.57(2), 307–315 (2003).
   PubMed Web of Science ®Google Scholar
• Mikhaeel NG, Timothy AR, Hain SF, O’Doherty MJ. 18-FDG–PET for the assessment of residual masses on CT following treatment of lymphomas. Ann. Oncol.11(Suppl. 1), 147ndash;150 (2000).
   PubMed Web of Science ®Google Scholar
• Naumann R, Vaic A, Beuthien-Baumann B et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Br. J. Haematol.115(4), 793–800 (2001).
   PubMed Web of Science ®Google Scholar
• Panizo C, Perez-Salazar M, Bendandi M et al. Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin’s disease mediastinal masses. Leuk. Lymphoma45(9), 1829–1833 (2004).
   PubMed Web of Science ®Google Scholar
• Rahmouni A, Luciani A, Itti E. Quantitative CT analysis for assessing response in lymphoma (Cheson’s criteria). Cancer Imaging5(Spec. No A), S102–S106 (2005).
   Google Scholar
• Reinhardt MJ, Herkel C, Altehoefer C, Finke J, Moser E. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin’s and non-Hodgkin’s lymphoma patients: when do we really need FDG–PET? Ann. Oncol.16(9), 1524–1529 (2005).
   PubMed Web of Science ®Google Scholar
• Reske SN. PET and restaging of malignant lymphoma including residual masses and relapse. Eur. J. Nucl. Med. Mol. Imaging30(Suppl. 1), S89–S96 (2003).
   PubMed Web of Science ®Google Scholar
• Rigacci L, Castagnoli A, Dini C et al.18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin’s lymphoma: long-term results. Oncol. Rep.14(5), 1209–1214 (2005).
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin’s disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br. J. Haematol.115(2), 272–278 (2001).
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [18F]FDG–PET a valid alternative to conventional diagnostic methods? J. Clin. Oncol.19(2), 414–419 (2001).
   Google Scholar
• Weihrauch MR, Re D, Scheidhauer K et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood98(10), 2930–2934 (2001).
   PubMed Web of Science ®Google Scholar
• Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica91(4), 522–529 (2006).
   PubMedGoogle Scholar
• Zinzani PL, Musuraca G, Alinari L et al. Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. Clin. Lymphoma Myeloma7(4), 291–295 (2007).
   PubMedGoogle Scholar
• Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol.25(5), 579–586 (2007).
   PubMed Web of Science ®Google Scholar
• Juweid ME, Stroobants S, Hoekstra OS et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J. Clin. Oncol.25(5), 571–578 (2007).
   PubMed Web of Science ®Google Scholar
• Brepoels L, Stroobants S, De Wever W et al. Hodgkin lymphoma: response assessment by revised International Workshop Criteria. Leuk. Lymphoma48(8), 1539–1547 (2007).
   PubMed Web of Science ®Google Scholar
• Yahalom J. Omitting radiotherapy after attaining FDG-PET-negative status following chemotherapy alone for Hodgkin lymphoma: a randomized study caveat. Leuk. Lymphoma48(9), 1667–1669 (2007).
   PubMed Web of Science ®Google Scholar
• Picardi M, De Renzo A, Pane F et al. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin’s lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk. Lymphoma48(9), 1721–1727 (2007).
   PubMed Web of Science ®Google Scholar
• Kobe C, Dietlein M, Franklin J et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first line chemotherapy in advanced-stage Hodgkin lymphoma. Blood (2008).
   Google Scholar
• Jacene HA, Filice R, Kasecamp W, Wahl RL. 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. J. Nucl. Med.50(1), 8–17 (2009).
   PubMedGoogle Scholar
• Bodet-Milin C, Kraeber-Bodere F, Dupas B et al. Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin’s lymphoma by 18F-fluorodeoxyglucose positron emission tomography. Haematologica93(3), 390–397 (2008).
   PubMed Web of Science ®Google Scholar
• Girinsky T, Pichenot C, Beaudre A, Ghalibafian M, Lefkopoulos D. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin’s disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int. J. Radiat. Oncol. Biol. Phys.64(1), 218–226 (2006).
   PubMedGoogle Scholar
• Girinsky T, van der Maazen R, Specht L et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother. Oncol.79(3), 270–277 (2006).
   PubMed Web of Science ®Google Scholar
• Specht L, Gray RG, Clarke MJ, Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin’s disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin’s Disease Collaborative Group. J. Clin. Oncol.16(3), 830–843 (1998).
   PubMed Web of Science ®Google Scholar
• Yahalom J. Transformation in the use of radiation therapy of Hodgkin lymphoma: new concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT). Eur. J. Haematol.66(Suppl.), 90–97 (2005).
   Google Scholar
• Gregoire V. Is there any future in radiotherapy planning without the use of PET: unraveling the myth. Radiother. Oncol.73(3), 261–263 (2004).
   PubMed Web of Science ®Google Scholar
• Jarritt PH, Carson KJ, Hounsell AR, Visvikis D. The role of PET/CT scanning in radiotherapy planning. Br. J. Radiol.79(Spec. No 1), S27–S35 (2006).
   Google Scholar
• Berthelsen AK, Dobbs J, Kjellén E et al. What’s new in target volume definitions for radiologists in ICRU Report 71? How can the ICRU volume definitions be integrated in clinical practice? Cancer Imaging11(7), 104–116 (2007).
   Google Scholar
• Specht L. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas. Semin. Radiat. Oncol.17(3), 190–197 (2007).
   PubMed Web of Science ®Google Scholar
• van Baardwijk A, Baumert BG, Bosmans G et al. The current status of FDG–PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat. Rev.32(4), 245–260 (2006).
   PubMed Web of Science ®Google Scholar
• Dizendorf EV, Baumert BG, von Schulthess GK, Lutolf UM, Steinert HC. Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy. J. Nucl. Med.44(1), 24–29 (2003).
   PubMed Web of Science ®Google Scholar
• Lee YK, Cook G, Flower MA et al. Addition of 18F-FDG–PET scans to radiotherapy planning of thoracic lymphoma. Radiother. Oncol.73(3), 277–283 (2004).
   PubMed Web of Science ®Google Scholar
• Girinsky T, Ghalibafian M, Bonniaud G et al. Is FDG–PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting? Radiother. Oncol.85(2), 178–186 (2007).
   PubMed Web of Science ®Google Scholar
• Hutchings M, Berthelsen AK, Loft A, Hansen M, Specht L. Clinical impact of FDG–PET/CT in the planning of radiotherapy for early stage Hodgkin lymphoma. Eur. J. Haematol.78(3), 206–212 (2007).
   PubMed Web of Science ®Google Scholar
• Krasin MJ, Hudson MM, Kaste SC. Positron emission tomography in pediatric radiation oncology: integration in the treatment-planning process. Pediatr. Radiol.34(3), 214–221 (2004).
   PubMedGoogle Scholar
• Jerusalem G, Beguin Y, Fassotte MF et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease. Ann. Oncol.14(1), 123–130 (2003).
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Tani M, Trisolini R et al. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. Haematologica92(6), 771–777 (2007).
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87–2 protocol – a groupe d’Etude des lymphomes de l’Adulte study. J. Clin. Oncol.18(16), 3025–3030 (2000).
   PubMed Web of Science ®Google Scholar
• Stiff PJ, Dahlberg S, Forman SJ et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin’s lymphoma: value of augmented preparative regimens – a Southwest Oncology Group trial. J. Clin. Oncol.16(1), 48–55 (1998).
   PubMed Web of Science ®Google Scholar
• Becherer A, Mitterbauer M, Jaeger U et al. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG–PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia16(2), 260–267 (2002).
   PubMed Web of Science ®Google Scholar
• Cremerius U, Fabry U, Wildberger JE et al. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin’s lymphoma. Bone Marrow Transplant.30(2), 103–111 (2002).
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood102(1), 53–59 (2003).
   PubMed Web of Science ®Google Scholar
• Filmont JE, Czernin J, Yap C et al. Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest124(2), 608–613 (2003).
   PubMed Web of Science ®Google Scholar
• Engles JM, Quarless SA, Mambo E, Ishimori T, Cho SY, Wahl RL. Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy. J. Nucl. Med.47(4), 603–608 (2006).
   PubMedGoogle Scholar
• Buck AK, Halter G, Schirrmeister H et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J. Nucl. Med.44(9), 1426–1431 (2003).
   PubMed Web of Science ®Google Scholar
• Sandherr M, von Schilling C, Link T et al. Pitfalls in imaging Hodgkin’s disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose. Ann. Oncol.12(5), 719–722 (2001).
   PubMedGoogle Scholar
• Martiat P, Ferrant A, Labar D et al.In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin’s lymphoma using positron emission tomography. J. Nucl. Med.29(10), 1633–1637 (1988).
   PubMed Web of Science ®Google Scholar
• Shields AF, Mankoff DA, Link JM et al. Carbon-11-thymidine and FDG to measure therapy response. J. Nucl. Med.39(10), 1757–1762 (1998).
   PubMed Web of Science ®Google Scholar
• Shields AF, Grierson JR, Dohmen BM et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat. Med.4(11), 1334–1336 (1998).
   PubMed Web of Science ®Google Scholar
• Buchmann I, Neumaier B, Schreckenberger M, Reske S. [18F]3´-deoxy-3´-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations – a pilot study. Cancer Biother. Radiopharm.19(4), 436–442 (2004).
   PubMed Web of Science ®Google Scholar
• Buck AK, Bommer M, Stilgenbauer S et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res.66(22), 11055–11061 (2006).
   PubMed Web of Science ®Google Scholar
• Kasper B, Egerer G, Gronkowski M et al. Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET. Leuk. Lymphoma48(4), 746–753 (2007).
   PubMed Web of Science ®Google Scholar
• Buck AK, Kratochwil C, Glatting G et al. Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT. Eur. J. Nucl. Med. Mol. Imaging34(11), 1775–1782 (2007).
   PubMedGoogle Scholar
• Graf N, Herrmann K, den Hollander J et al. Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment. Mol. Imaging Biol.10(6), 349–355 (2008).
   PubMed Web of Science ®Google Scholar
• Hoffman RM. Altered methionine metabolism, DNA methylation and oncogene expression in carcinogenesis. A review and synthesis. Biochim. Biophys. Acta738(1–2), 49–87 (1984).
   PubMed Web of Science ®Google Scholar
• Stern PH, Wallace CD, Hoffman RM. Altered methionine metabolism occurs in all members of a set of diverse human tumor cell lines. J. Cell Physiol.119(1), 29–34 (1984).
   PubMed Web of Science ®Google Scholar
• Wheatley DN. On the problem of linear incorporation of amino acids into cell protein. Experientia38(7), 818–820 (1982).
   PubMedGoogle Scholar
• Ogawa T, Kanno I, Hatazawa J et al. Methionine PET for follow-up of radiation therapy of primary lymphoma of the brain. Radiographics14(1), 101–110 (1994).
   PubMedGoogle Scholar